BCRX Q3 2021 Earnings — BioCryst Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

BCRXBioCryst Pharmaceuticals, Inc.

$2B

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$41M+571.8% YoY

Gross Profit

$40M98.5% margin

Operating Income

-$45M-108.8% margin

Net Income

-$59M-143.4% margin

EPS (Diluted)

$-0.33

QoQ Revenue Growth

-17.9%

Cash Flow

Operating Cash Flow

-$23M

Free Cash Flow

-$24M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$266M

Total Liabilities

$413M

Stockholders' Equity

-$147M

Cash & Equivalents

$200M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$41M	$6M	+571.8%
Gross Profit	$40M	$5M	+782.4%
Operating Income	-$45M	-$43M	-4.0%
Net Income	-$59M	-$46M	-27.5%

Revenue Segments

Collaborative and Other Research and Development

$2M100%